Intrinsic Value of S&P & Nasdaq Contact Us

PolyPid Ltd. PYPD NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • IL • USD

SharesGrow Score
56/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.50
+114.9%

PolyPid Ltd. (PYPD) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 8 Buy, 1 Hold.

The consensus price target is $9.50 (low: $9.00, high: $10.00), representing an upside of 114.9% from the current price $4.42.

Analysts estimate Earnings Per Share (EPS) of $-4.58 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-4.91 vs est $-4.58 (missed -7.1%). 2025: actual $-2.09 vs est $-2.09 (beat +0.1%). Analyst accuracy: 97%.

PYPD Stock — 12-Month Price Forecast

$9.50
▲ +114.93% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for PolyPid Ltd., the average price target is $9.50, with a high forecast of $10.00, and a low forecast of $9.00.
The average price target represents a +114.93% change from the last price of $4.42.
Highest Price Target
$10.00
Average Price Target
$9.50
Lowest Price Target
$9.00

PYPD Analyst Ratings

Buy
9
Ratings
8 Buy
1 Hold
Based on 9 analysts giving stock ratings to PolyPid Ltd. in the past 3 months
Rating breakdown
Buy
8 89%
Hold
1 11%
89%
Buy
8 analysts
11%
Hold
1 analysts
0%
Sell
0 analysts

EPS Estimates — PYPD

97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual –$4.91 vs Est –$4.58 ▼ 6.6% off
2025 Actual –$2.09 vs Est –$2.09 ▲ 0.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — PYPD

Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message